Role of methylenetetrahydrofolate reductase 677C->T polymorphism in the development of premature myocardial infarction

Atherosclerosis

Volumn 200, Issue 1, 2008, Pages 115-120

  Rallidis, Loukianos S ^a   Gialeraki, Argiro ^a   Komporozos, Christoforos ^a   Vavoulis, Panagiotis ^b   Pavlakis, Georgios ^b   Travlou, Anthi ^a   Lekakis, Ioannis ^a   Kremastinos, Dimitrios T ^a  

^a IASO GENERAL HOSPITAL   (Greece)

^b GENERAL HOSPITAL OF NIKEA   (Greece)

Author keywords

Homocysteine; MTHFR polymorphism; Premature myocardial infarction; Risk factors

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LIPID;

ADULT; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; FEMALE; FOLIC ACID BLOOD LEVEL; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HOMOZYGOSITY; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; VITAMIN BLOOD LEVEL;

ADULT; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY VESSELS; FEMALE; FOLIC ACID; GENETIC PREDISPOSITION TO DISEASE; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MYOCARDIAL INFARCTION; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 49949090230     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.12.016     Document Type: Article

References (31)

1. Choudhury I., and Marsh J.D. Myocardial infarction in young patients. Am J Med 107 (1999) 254-261
2. Doughty M., Mehta R., Bruckman D., et al. Acute myocardial infarction in the young: the University of Michigan experience. Am Heart J 143 (2002) 56-62
3. Zimmerman F.H., Cameron A., Fisher L.D., and Ng G. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 26 (1995) 654-661
4. Panagiotakos D.B., Rallidis L.S., Pitsavos C., Stefanadis C., and Kremastinos D. Cigarette smoking and myocardial infarction in young men and women: a case-control study. Int J Cardiol 116 (2007) 371-375
5. Kardasz I., and De Caterina R. Myocardial infarction with normal coronary arteries: a conundrum with multiple aetiologies and variable prognosis: an update. J Intern Med 261 (2007) 330-348
6. Verheugt F.W., Ten Cate J.W., Sturk A., et al. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol 59 (1987) 1075-1079
7. Rallidis L.S., Belesi C.I., Manioudaki H.S., et al. Myocardial infarction under the age of 36: prevalence of thrombophilic disorders. Thromb Haemost 90 (2003) 272-278
8. Romagnoli E., and Lanza G.A. Acute myocardial infarction with normal coronary arteries: role of coronary artery spasm and arrhythmic complications. Int J Cardiol 117 (2007) 3-5
9. Wald D.S., Law M., and Morris J.K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325 (2002) 1202-1206
10. Ford E.S., Smith S.J., Stroup D.F., Steinberg K.K., and Mueller P.W. Homocyst(e)ine and cardiovascular disease: a systemic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 31 (2002) 59-70
11. Zee R.Y., Mora S., Cheng S., et al. Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C->T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. Clin Chem 53 (2007) 807-809
12. Kaul S., Zadeh A.A., and Shah P.K. Homocysteine hypothesis for atherothrombotic cardiovascular disease not validated. J Am Coll Cardiol 48 (2006) 914-923
13. Ogawa M., Abe S., Saigo M., et al. Homocysteine and hemostatic disorder as a risk factor for myocardial infarction at a young age. Thromb Res 109 (2003) 253-258
14. 12 and folate levels in premature coronary artery disease. BMC Cardiovasc Disord 6 (2006) 38
15. Nikfardjam M., Graf S., Hornykewycz S., et al. Homocysteine levels in young patients with coronary artery disease: relation to history of acute myocardial infarction and anatomical extent of disease. Thromb Res 103 Suppl. 1 (2001) S35-S39
16. Schmitz C., Lindpaintner K., Verhoef P., Gaziano J.M., and Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction: a case-control study. Circulation 94 (1996) 1812-1814
17. Ma J., Stampfer M.J., Hennekens C.H., et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 94 (1996) 2410-2416
18. Jee S.H., Beaty T.H., Suh I., Yoon Y., and Appel L.J. The methylenetetrahydrofolate reductase gene is associated with increased cardiovascular risk in Japan, but not in other populations. Atherosclerosis 153 (2000) 161-168
19. Klerk M., Verhoef P., Clarke R., et al., MTHFR Studies Collaboration Group. MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 288 (2002) 2023-2031
20. Lewis S.J., Ebrahim S., and Smith G.D. Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate?. BMJ 331 (2005) 1053
21. Gallagher P.M., Meleady R., Shields D.C., et al. Homocysteine and risk of premature coronary heart disease: evidence for a common gene mutation. Circulation 94 (1996) 215-2158
22. Mager A., Lalezari S., Shohat T., et al. Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease. Circulation 100 (1999) 2406-2410
23. Gülec S., Aras O., Akar E., et al. Methylenetetrahydrofolate reductase gene polymorphism and risk of premature myocardial infarction. Clin Cardiol 24 (2001) 281-284
24. Schwartz S.M., Siscovick D.S., Malinow M.R., et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 96 (1997) 412-417
25. Christensen B., Frosst P., Lussier-Cacan S., et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 17 (1997) 569-573
26. Pintó X., Vilaseca M.A., Garcia-Giralt N., et al., Baix Llobregat Homocysteine Study Group. Homocysteine and the risk of MTHFR 677C->T allele in premature coronary artery disease: case control and family studies. Eur J Clin Invest 31 (2001) 24-30
27. Welch G.N., and Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 338 (1998) 1042-1050
28. Durand P., Lussier-Cacan S., and Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J 11 (1997) 1157-1168
29. Khajuria A., and Houston D.S. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Blood 96 (2000) 966-972
30. Midorikawa S., Sanada H., Hashimoto S., and Watanabe T. Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from vascular endothelial and smooth muscle cells. Biochem Biophys Res Commun 272 (2000) 182-185
31. Yamaguchi H., Homma Y., and Handa S. Biochemical markers of vasospastic coronary artery disease. Nutr Metab Cardiovasc Dis 13 (2003) 365-371